
Email updates

Keep up to date with the latest news and content from Arthritis Research & Therapy and BioMed Central.

Research article

Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab

Xenofon Baraliakos1, Joachim Listing2, Jan Brandt1, Martin Rudwaleit3, Joachim Sieper3 and Juergen Braun1*

Author Affiliations

1 Rheumazentrum Ruhrgebiet, Herne, Germany

2 German Rheumatism Research Center, Berlin, Germany

3 Charité, Medical University of Berlin, Campus Benjamin Franklin, Department of Rheumatology, Germany

For all author emails, please log on.

Arthritis Research & Therapy 2005, 7:R439-R444  doi:10.1186/ar1693

Published: 21 February 2005

Abstract

We analyzed the clinical response and the time to relapse after discontinuation of continuous long-term infliximab therapy in patients with ankylosing spondylitis (AS). After 3 years of infliximab therapy, all AS patients (n = 42) discontinued treatment (time point (TP)1) and were visited regularly for 1 year in order to assess the time to relapse (TP2). Relapse was defined as an increase to a value ≥ 4 on the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and a physician's global assessment ≥ 4 according to the recommendations of the Assessments in Ankylosing Spondylitis (ASAS) working group. After 52 weeks, 41 of the 42 patients (97.6%) had to be reinfused because of relapse. The mean change in the BASDAI between TP1 and TP2 was 3.6 ± 1.7 and that in the physician's global assessment was 4.4 ± 1.8 (both P < 0.001). The mean time to relapse was 17.5 weeks (± 7.9 weeks, range 7 to 45). Ten patients (24%) showed a relapse within 12 weeks and 38 patients (90.5%), within 36 weeks. After 52 weeks, only one patient had remained in ongoing remission without further treatment with anti-tumor-necrosis factor. Patients who were in partial remission according to the ASAS criteria and those with normal C-reactive protein levels at the time point of withdrawal had longer times to relapse after discontinuation of the treatment. Retreatment with infliximab was safe and resulted in clinical improvement in all patients to a state similar to that before the treatment was stopped. Discontinuation of long-term therapy with infliximab eventually led to relapse of disease activity in all patients but one.
{"cc_re__cc_re__cc_by_2_0": ["rthritis Research & Therapy 2005 7:R439\" />\r\n<meta name=\"dc.format\" content=\"text/html\" />\r\n<meta name=\"dc.publisher\" content=\"BioMed Central Ltd\" />\r\n<meta name=\"dc.date\" content=\"2005-02-21\" />\r\n<meta name=\"dc.type\" content=\"Research article\" />\r\n<meta name=\"dc.identifier\" content=\"10.1186/ar1693\" />\r\n<meta name=\"dc.identifier\" content=\"info:pmid/15899030\" />\r\n<meta name=\"dc.language\" content=\"en\" />\r\n<meta name=\"dc.copyright\" content=\"2005 Baraliakos et al.; licensee BioMed Central Ltd.\" />\r\n<meta name=\"dc.rights\" content=\"http://creativecommons.org/licenses/by/2.0/\" />\r\n<meta name=\"dc.rightsAgent\" content=\"reprints@biomedcentral.com\" />\r\n\r\n<meta name=\"prism.issn\" content=\"1478-6354\" />\r\n<meta name=\"prism.publicationName\" content=\"Arthritis Research & Therapy\" />\r\n<meta name=\"prism.publicationDate\" content=\"2005-02-21\" />\r\n<meta name=\"prism.volume\" content=\"7\" />\r\n<meta name=\"prism.number\" content=\"3\" />\r\n<meta name=\"prism.section\" content=\"Research article\" />\r\n<meta name=\"prism.startingPage\" content=\"R439\" />\r\n<meta name=\"prism.copyright\" content=\"2005 Baral"], "copyright__copyright__copyright": ["factor. Patients who were in partial remission according to the ASAS criteria and those with normal C-reactive protein levels at the time point of withdrawal had longer times to relapse after discontinuation of the treatment. Retreatment with infliximab was safe and resulted in clinical improvement in all patients to a state similar to that before the treatment was stopped. Discontinuation of long-term therapy with infliximab eventually led to relapse of disease activity in all patients but one.", "factor. Patients who were in partial remission according to the ASAS criteria and those with normal C-reactive protein levels at the time point of withdrawal had longer times to relapse after discontinuation of the treatment. Retreatment with infliximab was safe and resulted in clinical improvement in all patients to a state similar to that before the treatment was stopped. Discontinuation of long-term therapy with infliximab eventually led to relapse of disease activity in all patients but one.", "factor. Patients who were in partial remission according to the ASAS criteria and those with normal C-reactive protein levels at the time point of withdrawal had longer times to relapse after discontinuation of the treatment. Retreatment with infliximab was safe and resulted in clinical improvement in all patients to a state similar to that before the treatment was stopped. Discontinuation of long-term therapy with infliximab eventually led to relapse of disease activity in all patients but one.", "factor. Patients who were in partial remission according to the ASAS criteria and those with normal C-reactive protein levels at the time point of withdrawal had longer times to relapse after discontinuation of the treatment. Retreatment with infliximab was safe and resulted in clinical improvement in all patients to a state similar to that before the treatment was stopped. Discontinuation of long-term therapy with infliximab eventually led to relapse of disease activity in all patients but one.", "factor. Patients who were in partial remission according to the ASAS criteria and those with normal C-reactive protein levels at the time point of withdrawal had longer times to relapse after discontinuation of the treatment. Retreatment with infliximab was safe and resulted in clinical improvement in all patients to a state similar to that before the treatment was stopped. Discontinuation of long-term therapy with infliximab eventually led to relapse of disease activity in all patients but one."]}